An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants

April 8, 2021 updated by: Bristol-Myers Squibb

A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BMS-986259 in Healthy Participants.

A Randomized double blind, placebo controlled study of BMS-986259 to evaluate the safety and effectiveness of the drug amongst different conditions and populations.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
132

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
      • Groningen, Netherlands, 9728 NZ
        • PRA Health Sciences - Groningen
  • United Kingdom
      • London, United Kingdom, SE1 1YR
        • Richmond Pharmacology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy participants with a body mass Index (BMI) of 18.0 kg/m^2 - 30.0 kg/m^2.
  • Males and females not of child bearing potential.
  • Participants in the Japanese Cohorts in Part C must be first-generation Japanese (born in Japan, not living outside of Japan for more than 10 years, and both parents are ethnically Japanese.)

Exclusion Criteria:

  • Any previous dosing in another cohort in the current study or participation in an investigational drug within 2 months prior to (the first) drug administration in the current study.
  • Any Significant Acute or Chronic medical Illness, major surgery in 12 months, or so smoking or used smoking cessation in 3 months.
  • Inability to be venipunctured and/or tolerate venous access. ,abnormalities in hemoglobin or positive screen for hepatitis C, Hepatitis B, Human Immunodeficiency Virus (HIV), including hepatic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Part A SAD - A1 Cohort
Single Ascending Dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part A SAD - A2 Cohort
Single Ascending dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part A SAD- A3 Cohort
Single Ascending dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part A SAD- A4 Cohort
Single Ascending dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part A SAD - A5 Cohort
Single Ascending dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part A SAD- A6 Cohort
Single Ascending dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part B MAD- B1 Cohort
Multiple Ascending Dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part B MAD - B2 Cohort
Multiple Ascending Dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part B MAD - B3 Cohort
Multiple Ascending Dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part B MAD - B4 Cohort
Multiple Ascending Dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part C JMAD - C1 Cohort
Japanese Multiple Ascending Dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part C JMAD - C2 Cohort
Japanese Multiple Ascending Dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent
Experimental: Part C JMAD - C3 Cohort
Japanese Multiple Ascending Dose
Drug: BMS-986259
Single and Multiple ascending dose from Dose 1 to Dose 5
Other: Placebo
Placebo matching BMS-986259
Diagnostic test: P-Aminohippurate
Diagnostic Agent
Diagnostic test: Iohexol
Diagnostic Agent

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Incidence of Adverse Events (AEs)
Time Frame: Up to 7 weeks
Up to 7 weeks
Incidence of Serious Adverse Events (SAEs)
Time Frame: up to 7 weeks
up to 7 weeks
AEs leading to discontinuation
Time Frame: Up to 7 weeks
Up to 7 weeks
Number of clinically significant changes in vital signs
Time Frame: Up to 7 weeks
Up to 7 weeks
Number of clinically significant changes in ECG (electrocardiogram)
Time Frame: Up to 7 weeks
Up to 7 weeks
Number of clinically significant changes in physical examinations
Time Frame: Up to 7 weeks
Up to 7 weeks
Number of clinically significant changes in clinical laboratory tests
Time Frame: Up to 7 weeks
Up to 7 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Maximum observed concentration(Cmax)- Part A SAD
Time Frame: up to 7 weeks
up to 7 weeks
Time of maximum observed concentration(Tmax)- Part A SAD
Time Frame: Up to 7 weeks
Up to 7 weeks
Terminal elimination rate constant (Lz)-Part A SAD
Time Frame: up to 7 weeks
up to 7 weeks
Half life (T-HALF)- Part A SAD
Time Frame: Up to 7 weeks
Up to 7 weeks
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration(AUC(0-T)- Part A SAD
Time Frame: Up to 7 weeks
Up to 7 weeks
Area under the concentration-time curve from time zero extrapolated to infinite time(AUC(INF)-Part A SAD
Time Frame: Up to 7 weeks
Up to 7 weeks
Apparent total body clearance(CL/F)-Part A SAD
Time Frame: Up to 7 weeks
Up to 7 weeks
Apparent volume of distribution at terminal phase(Vz/F)- Part A SAD
Time Frame: Up to 7 weeks
Up to 7 weeks
Maximum observed concentration(Cmax)-Part B and Part C MAD
Time Frame: Up to 7 years
For day 1 , day 13 and day 14
Up to 7 years
Time of maximum observed concentration(Tmax)-Part B and Part C MAD
Time Frame: Up tp 7 weeks
For day 1, day 13 and day 14
Up tp 7 weeks
Area under the concentration-time curve in one dosing interval(AUC(TAU)- Part B and Part C MAD
Time Frame: Up to 7 weeks
For day 1 and day 14
Up to 7 weeks
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration(AUC(0-T)-Part B and Part C MAD
Time Frame: Up to 7 weeks
For Day 14
Up to 7 weeks
Terminal elimination rate constant (Lz)-Part B and Part C MAD
Time Frame: up to 7 weeks
For day 14
up to 7 weeks
Half life (T-HALF)- Part B and Part C MAD
Time Frame: Up to 7 weeks
For day 14
Up to 7 weeks
Apparent total body clearance(CL/F)-Part B and Part C MAD
Time Frame: Up to 7 weeks
For day 14
Up to 7 weeks
Apparent volume of distribution at terminal phase(Vz/F)- Part B and Part C MAD
Time Frame: Up to 7 weeks
For day 14
Up to 7 weeks
Accumulation Ratio Cmax (AR(Cmax)-Part B and Part C MAD
Time Frame: Up to 7 weeks
For day 14
Up to 7 weeks
Accumulation Ratio AUC(TAU) (AR(AUC[TAU])- Part B and Part C MAD
Time Frame: Up to 7 weeks
for day 14
Up to 7 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 18, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 4, 2021

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 4, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 20, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 2, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 5, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 9, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 8, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CV019-002

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Participants

Clinical Trials on BMS-986259

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings